Alta Mira Treatment Outcomes
Alta Mira Recovery Programs is committed to monitoring patient progress in treatment and to measuring and improving treatment outcomes. Vista Research Group is an independent research group that was founded in 2015 to help treatment programs cost-effectively measure and improve their success rates. The following results from the first 9 months of the research were published in May 2019.
Vista Research Group Background
Vista Research Group gathered data from participating Alta Mira clients at four points – early in their stay at the center, one month after leaving treatment, six months after leaving treatment, and one year after leaving treatment. Vista collects treatment outcomes using validated research methodologies. Alta Mira began enrolling clients in INSIGHT Addiction™ — the tool Vista Research uses for measuring our outcome data—on July 18, 2018. This report summarizes data recorded between July 18, 2018 and April 30, 2019.
As part of their Intake Questionnaire, the patients were asked a series of screening questions about the 30 days before they started treatment. If they answered one or more of the screening questions for a particular co-occurring disorder positively, they were then taken to a full academically-validated instrument to measure the severity of their symptoms of that disorder.
INSIGHT Addiction™ uses the following instruments that have been academically-validated for self-report:
- Depression: PHQ-9
- Anxiety: GAD-7
- Trauma: PCL-6
- Suicidal Thoughts & Behavior: Columbia Suicide Severity Rating Scale
- Eating Disorders: Dr. Eric Stice’s EDDS questions as modified for DSM-5
Patient Characteristics at Intake
Overall Feeling Prior to Treatment
- Slightly more than half of patients (54%) were male.
- Patients were mostly white (89%).
- The median age was 39.
- 69% had received at least one degree.
- Just under half (49%) were employed prior to treatment, with 32% neither working nor studying by choice.
- Nearly all (91%) were in a stable living arrangement.
What Brought Patients to Treatment
- The largest group of patients (66%) entered treatment because they were asked to go by family or friends
- Almost as many (59%) had become tired of living the way they were
- 21% had been hospitalized immediately beforehand
Primary Drug of Choice
- Alcohol was the primary drug of choice for over half (55%) of the patients
- Marijuana was the primary drug of choice of 13% of patients
- 11% were using opiates with an additional 35 using heroin
- 81% of Alta Mira’s patients met the definition of having a severe alcohol or drug use disorder
- 35% of them reported having experienced all 11 of the DSM-5 SUD criteria in the year before starting treatment
Previous SUD Treatment
- Among the 71 patients, 59% had been in SUD treatment before, and 19% had been in treatment on 4 or more occasions
Patient Progress During Treatment—Symptom Reduction
Patient Progress on Depression Symptoms
- The majority of patients entering Alta Mira reported suffering moderate or severe symptoms of one or more co-occurring disorders in the 30 days prior to entering treatment
- During the time they were in treatment, the severity of depression symptoms that Alta Mira patients were experiencing declined dramatically
Patient Progress on Anxiety Symptoms
- During the time they were in treatment, the severity of anxiety symptoms that Alta Mira patients were experiencing declined dramatically
Patient Progress on Trauma Symptoms
- During the time they were in treatment, the severity of trauma symptoms that Alta Mira patients were experiencing declined dramatically
Reduced Suicidal Thoughts
- The level of patients reporting suicidal thoughts greatly reduced during treatment. Only 4% reported wishing they could go to sleep and not wake up on their last survey
Reason for Discharge
- Among the 58 clients who discharged from Alta Mira during the period between July 14, 2018 and April 30, 2019, 51 (88%) completed at least one level of care and 85% completed all recommended treatment
Patient Satisfaction With Treatment
- The majority (65%) of Alta Mira patients submitting ongoing progress monitoring surveys were very satisfied with the treatment they were receiving